Yousif Capital Management LLC Sells 2,421 Shares of Azenta, Inc. $AZTA

Yousif Capital Management LLC lowered its stake in Azenta, Inc. (NASDAQ:AZTA) by 14.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 14,909 shares of the company’s stock after selling 2,421 shares during the period. Yousif Capital Management LLC’s holdings in Azenta were worth $459,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Oppenheimer Asset Management Inc. boosted its holdings in shares of Azenta by 6.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 12,617 shares of the company’s stock valued at $437,000 after purchasing an additional 756 shares in the last quarter. Legacy Advisors LLC increased its stake in Azenta by 25.3% in the first quarter. Legacy Advisors LLC now owns 13,111 shares of the company’s stock valued at $454,000 after purchasing an additional 2,649 shares in the last quarter. Lecap Asset Management Ltd. acquired a new stake in Azenta in the first quarter valued at approximately $669,000. Peregrine Capital Management LLC lifted its stake in shares of Azenta by 3.4% in the first quarter. Peregrine Capital Management LLC now owns 154,470 shares of the company’s stock valued at $5,351,000 after buying an additional 5,093 shares in the last quarter. Finally, DAVENPORT & Co LLC raised its holdings in shares of Azenta by 4.1% in the first quarter. DAVENPORT & Co LLC now owns 27,438 shares of the company’s stock valued at $950,000 after purchasing an additional 1,090 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Azenta Stock Up 2.1%

Shares of Azenta stock opened at $32.39 on Friday. The firm has a market capitalization of $1.48 billion, a P/E ratio of -13.38 and a beta of 1.62. Azenta, Inc. has a 52 week low of $23.91 and a 52 week high of $55.63. The company has a 50 day moving average price of $30.54 and a 200 day moving average price of $29.68.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Azenta had a negative net margin of 18.45% and a positive return on equity of 1.35%. The company had revenue of $143.94 million during the quarter, compared to analyst estimates of $149.64 million. During the same period last year, the firm posted $0.14 EPS. Azenta’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts anticipate that Azenta, Inc. will post 0.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on AZTA shares. Raymond James Financial raised shares of Azenta from a “market perform” rating to an “outperform” rating and set a $35.00 price target on the stock in a research report on Wednesday, August 6th. Stephens initiated coverage on shares of Azenta in a research report on Tuesday, July 22nd. They issued an “equal weight” rating and a $35.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Azenta in a research report on Wednesday, October 8th. Finally, Evercore ISI set a $33.00 price target on shares of Azenta and gave the stock an “in-line” rating in a research note on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Azenta has an average rating of “Hold” and a consensus price target of $35.75.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.